Incyte (INCY) Briefing Doc on Retifanlimab Suggest Data May Be Insufficient to Support Approval - Mizuho
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Neutral rating and $95.00 price target on Incyte (NASDAQ: INCY) after briefing document ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
